Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-A medium term view on the U.S. dollar

Wed, 17th Mar 2021 12:48

* European Stoxx 600 down 0.5%

* Autos stock index best performer, up 1.8%

* BMW shares jump after strong 2021 forecast

* Verbund shares fall after results

March 17 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

A MEDIUM-TERM VIEW ON THE U.S. DOLLAR (1244 GMT)

The dollar is holding steady ahead of today’s Fed policy
meeting outcome after rising recently as a fresh spike in
Treasury yields re-ignited inflation fears and sparked a
sell-off in riskier currencies.

But this kind of relationship might change, if we take a
broader angle.

A Fed on hold well into 2023 is likely to see greater
pressure on the dollar on “deteriorating external account and
negative real yields,” according to Deutsche Bank, which sees
EUR/USD “rising and exceeding medium-term measures of purchasing
power parity of around 1.25.”

A new framework adopted by the central bank last year means
it will allow inflation to rise above its target for a period to
make inflation average 2% over time.

“Rising back-end yields and a weaker dollar are entirely
consistent with historical experience: the correlation between
the two has in the past been close to zero, and what matters
most for the dollar is front-end real yields,” according to
Deutsche Bank analysts.

A central bank that endorses a controlled overshoot of
inflation, as the Fed is supposed to do for a foreseeable
future, “is likely to do significant damage to the dollar.”

With U.S. fiscal stimulus targeting low income households
with high marginal propensity to consume, rising domestic demand
is expected to widen the current account deficit.

In the chart below the euro dollar rate (green)
recently falling as U.S. yields (orange) rise.

(Stefano Rebaudo)

*****

ESG FLOWS HYPE, BUT PERFORMANCE SLOWS (1152 GMT)

Flows into ESG strategies continue to gather momentum.

In the first two months of the year, $16.7 billion went into
long-term retail funds in the U.S. and $99.7 billion into non-US
funds, according to figures from Jefferies.

"In addition to positive flow momentum, new product launches
with ESG designations also continue to flourish," the analysts
add.

March marked a milestone for sustainable finance in Europe,
they add, with the launch of the Sustainable Finance Disclosure
Regulation (SFDR).

"It is designed to curb "greenwashing" throughout the entire
investment value chain (asset managers, pension funds, insurers
and advisers)".

From now on, products that do not take account of ESG
criteria will need to say so, while products promoting
environmental or social characteristics will need to say if they
are meeting their goals.

But so far in 2021, ESG investment performance has slowed
down compared to the previous year.

"The resurgence in value strategies, small caps and cyclical
industries have all been factors," Jefferies notes.

(Joice Alves)

*****

CHALLENGING TESLA IN THE STOCK MARKET (1058 GMT)

German carmakers' efforts to challenge the the world’s
leader in electric vehicles Tesla are starting to pay
off also in the stock market, it seems.

Deutsche Bank analysts recall that yesterday big tech stocks
did well despite rising interest rates, with retail favourites
still on the rise with one notable exception.

"One such favourite Tesla (-4.39%) was down on the day
though and it must be significant that VW's preferred shares
rose +6.71% on the company's plans of how they can beat Tesla to
be the world's leader in electric vehicles," they say.

Below the chart of Volkswagen (orange) and Tesla (blue)
stocks in the recent days.

It seems that retail investors have targeted Europe after
Volkswagen announced its ambitious plans on electrical driving.

BMW said today it expects at least half of its
sales to be zero emission vehicles by 2030, setting a more
conservative target than some rivals in the race to embrace
cleaner driving.

(Stefano Rebaudo)

*****

AUTOS STOCKS PROP UP THE STOXX 600 (0853 GMT)

European STOXX 600 index is just below the floating line
with autos stocks still on the rise after yesterday’s jump,
while commodities related stocks are in negative territory.

More good news is boosting the autos stock index,
which is up 1.4%, hitting a fresh two-year high.

Shares in BMW are up 4.4% after the company said
it expects a significant year-on-year increase in group pretax
profit in 2021.

Volkswagen’s ambitious expansion plans in electric driving
are also boosting the sector. Its shares are rising 2.3%.

Basic materials and oil and gas are among the
worst performers after their recent rally.

The STOXX 600 index is down 0.2%.

Financial markets across the globe are on hold ahead of the
Fed policy meeting outcome, which is expected to give clues
about next central bank’s moves on interest rates.

Eyes also on this week's first high-level, in-person contact
between Beijing and Washington since U.S. President Joe Biden
took office.

(Stefano Rebaudo)

*****

WHAT'S THE (DOT) PLOT, CHAIR POWELL? (0858 GMT)

It's Federal Reserve day and market focus is on the central
bank's rate-hike projections for 2023 in the so-called "dot
plot."

Some economists expect this to show the Fed now expects one
rate hike for 2023 versus none in December. An unchanged median
dot for 2023 could be interpreted as the Fed pushing back
against higher bond yields and markets' pricing of rate hikes.

The Fed will deliver its statement and economic forecasts at
1800 GMT, followed with a news briefing. Until then, barring
unforeseen events, markets will likely stay calm. Ten-year U.S.
yields are just off 13-month highs, the dollar index
is little changed and equity futures are a touch lower
.

The tone across world stocks is cautious too, with Asian
stocks tracking Wall Street's Tuesday fall and European markets
too set to open softer.

In the euro zone, it's the final day of voting in the Dutch
national election -- the first major general election in the EU
since the pandemic began.

Prime Minister Mark Rutte's VVD Party is expected to secure
a fourth term, but there is a risk markets are not adequately
pricing gains at the ballot for anti-establishment forces.

Some good news for AstraZeneca as Australia's
pharmaceutical regulator said the rollout of the company's
COVID-19 vaccine would continue, despite many European nations
pausing vaccinations to investigate reported side-effects.

The EU regulator will release findings on Thursday.

Elsewhere, Credit Agricole Italia has secured a
green light from European Central Bank supervisors for its
planned takeover bid of third-tier Italian lender Credito
Valtellinese .
Key developments that should provide more direction to markets
on Wednesday:

- Fed monetary policy decision and news conference.

- German, UK German new car registration data.

- US housing starts data due.

- Corporates: BMW said it expects a significant year-on-year
increase in pretax profit; Raiffeisen Bank aims to distribute
20%-50% of consolidated net profits; retail investment platform
Hargreaves Lansdown 2021 profit to beat expectations.

- Italy's biggest insurer Generali is studying an
acquisition in Russia worth nearly 2 billion euros ($2.4
billion), according to a media report.

(Dhara Ranasinghe)

*****

ON HOLD BEFORE THE FED (0628 GMT)

European stock futures are broadly unchanged along with
their U.S. peers as financial markets across the globe are on
hold before the U.S. Federal Reserve policy meeting outcome.

Investors are waiting for cues about central bank’s future
moves on interest rates after a jump in government bond yields
triggered by expectations of stronger than expected economic
growth and inflation.

Market will be closely watching also the first high-level
in-person contact between Beijing and Washington since U.S.
president Joe Biden took office. The meeting among Chinese and
U.S. officials will take place in Alaska on March 18 and 19.

(Stefano Rebaudo)

*****

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.